T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
Cette étude de cohorte rétrospective évalue le risque de second cancer primitif à cellules T après une immunothérapie à base de lymphocytes CAR-T
Genetically modified chimeric antigen receptor T-cell (CAR-T) therapy is a potent immunotherapy for several refractory hematologic malignant neoplasms (HMNs). However, concerns regarding second primary malignant neoplasms (SPMNs) after CAR-T therapy remain and are potentially associated with cumulative exposure to chemotherapeutic agents, prolonged immunosuppression, or insertional mutagenesis. The US Food and Drug Administration (FDA) issued a report about T-cell malignant neoplasms (TCMNs) emerging after CAR-T therapy. Yet, CAR-T therapy’s role in increased risk of SPMN remains uncertain, especially given the occurrence of SPMNs with alternative treatments for the same disease indications. This retrospective cohort study aimed to ascertain whether a disproportional increase in SPMN and TCMN reporting occurs after CAR-T therapy.